Biologic agents in islet transplantation.

Islet transplantation is today an accepted modality for treating selected patients with frequent hypoglycemic events or severe glycemic lability. Despite tremendous progress in islet isolation, culture, and preservation, clinical use is still restricted to a limited subset, and lifelong immunosuppression is required. Issues surrounding limited islet revascularization and immune destruction remain. One of the major challenges is to prevent alloreactivity and recurrence of autoimmunity against ß-cells. These two hurdles can be effectively reduced by immunosuppressive therapy combining induction and maintenance treatments. The introduction of highly potent and selective biologic agents has significantly reduced the frequency of acute rejection and has prolonged graft survival, while minimizing the complications of this therapeutic scheme. This review will address the most important biological agents used in islet transplantation. We provide a historical perspective of their introduction into clinical practice and their role in current clinical protocols, aiming at improved engraftment efficiency, increased long-term survival, and better overall results of clinical islet transplantation.

Tudor Griffith, gap junctions and conducted vasodilatation: electromechanical coupling back in the limelight.

Tudor Griffith's untimely death cut short a research career focused on the mechanisms regulating vascular tone and blood flow. This brief review highlights the contribution that Tudor's work made to 3 main areas: the early days of study toward elucidating the identity of the endothelium-derived relaxing factor (or nitric oxide), the use of computational modeling to unravel the mechanisms underlying the rhythmical arterial contractions known as vasomotion, and the role played by gap junctions in the vasodilatation attributed to endothelium-derived hyperpolarization. Tudor's pioneering application of the connexin mimetic peptides as selective gap junction antagonists has contributed substantially to the current state of knowledge on the role of cell coupling in arterial function. Together, these studies have reemphasized the importance of electromechanical coupling by which changes in membrane potential can rapidly control vessel diameter and blood flow.

[A short history of anti-rheumatic therapy--VII. Biological agents]. / Piccola storia della terapia antireumatica--VII. I farmaci "biologici".

The introduction of biological agents has been a major turning-point in the treatment of rheumatic diseases, particularly in rheumatoid arthritis. This review describes the principle milestones that have led, through the knowledge of the structure and functions of nucleic acids, to the development of production techniques of the three major families of biological agents: proteins, monoclonal antibodies and fusion proteins. A brief history has also been traced of the cytokines most involved in the pathogenesis of inflammatory rheumatic diseases (IL-1 and TNF) and the steps which have led to the use of the main biological drugs in rheumatology: anakinra, infliximab, adalimumab, etanercept and rituximab.

Research achievement award--D. John Faulkner.

David John Faulkner, one of the pioneers of marine natural products chemistry and the 2003 recipient of the ASP Research Achievement Award, passed away on November 23, 2002. John was very pleased to learn that he'd been named as the award recipient and was intending to present the ASP Research Achievement Award Address at the annual meeting in July 2003, Chapel Hill, North Carolina. John's untimely death left an unprecedented event in the history of the ASP-a posthumous Research Achievement Award to a deserving individual and an untimely loss for us all. We are bereft of a colleague, a friend, and a mentor, and the opportunity to hear John's words on the occasion of his own award. In tribute to John, we have assembled a retrospective of John's work that is not meant to be a comprehensive review (this would take considerably more space) but a selection of highlights and personal vignettes from some of those that trained in marine natural products under his mentorship. This paper is a written account of the symposium presented by the authors at the ASP Annual Meeting in Chapel Hill, North Carolina, on July 16, 2003.

Personal recollections on the early development of taxol.

All of us who have worked with taxol in the laboratory and the clinic, and the many patients all over the world who have benefited from the drug, owe a great debt of gratitude to Monroe Wall, Mansukh Wani, and their colleagues for the initial isolation and characterization of this compound.

The natural functions of secondary metabolites.

Secondary metabolites, including antibiotics, are produced in nature and serve survival functions for the organisms producing them. The antibiotics are a heterogeneous group, the functions of some being related to and others being unrelated to their antimicrobial activities. Secondary metabolites serve: (i) as competitive weapons used against other bacteria, fungi, amoebae, plants, insects, and large animals; (ii) as metal transporting agents; (iii) as agents of symbiosis between microbes and plants, nematodes, insects, and higher animals; (iv) as sexual hormones; and (v) as differentiation effectors. Although antibiotics are not obligatory for sporulation, some secondary metabolites (including antibiotics) stimulate spore formation and inhibit or stimulate germination. Formation of secondary metabolites and spores are regulated by similar factors. This similarity could insure secondary metabolite production during sporulation. Thus the secondary metabolite can: (i) slow down germination of spores until a less competitive environment and more favorable conditions for growth exist; (ii) protect the dormant or initiated spore from consumption by amoebae; or (iii) cleanse the immediate environment of competing microorganisms during germination.

La enfermedad en la historia : una aproximación política, cultural y socioeconómica / The disease in the history

El orden médico y el concepto salud-enfermedad. La enfermedad desde la antiguedad hasta el Renacimiento. Las ciencias y la Filosofía. Concepción histórico-social de la enfermedad. Concepción biológica o biologista. La construcción social del criterio de normal y su circulación discursiva.El proceso salud-enfermedad